Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Profit & Loss 
Valuation 
Analyst Note 
Balance Sheet 
Cash Flow 
Financial Ratio 
Qtr. Results 
News 
About
Anuh Pharma Ltd (ANUHPHR)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506260 NSE: ANUHPHR Pharmaceuticals & Drugs | Small Cap | Anuh Pharma Share Price
₹79.57 0.44 (0.56%)
As on 27-Jul'26 10:19
Anuh Pharma Ltd (ANUHPHR)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506260 NSE: ANUHPHR Pharmaceuticals & Drugs | Small Cap | Anuh Pharma Share Price
₹79.57 0.44 (0.56%)
As on 27-Jul'26 10:19
Key Metrics
Valuation Multiples
Market Cap
₹793 Cr.
Current Price
₹79.6
52-Week Low / High
₹67 / 104
TTM EPS
₹4.1
TTM Sales
₹772 Cr.
Book Value per Share
₹35.1
P/E Ratio
19.32
Higher than its 5-year historical median
Industry PE
52.9
Price to Book (P/B)
2.25
Lower than its 5-year historical median
Price to Sales (P/S)
1.03
Lower than its 5-year historical median
EV/EBITDA
11.79
In line with its 5-year historical median
Dividend Yield
1.89%
Profitability Efficiency
Return on Equity (ROE)
12.10%
Outperforms industry median
Return on Capital Employed (ROCE)
16.02%
Outperforms industry median
Return on Assets (ROA)
7.76%
Operating Profit Margin
8.9%
Net Profit Margin
5.32%
Gross Profit Margin
8.4%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
16.65%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-6.65%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-13.31%
Asset Quality
Promoter Holding
71.80%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹302 Cr.
Equity
₹50.1 Cr.
Face Value
₹5
All Time Low / High
₹0.02 / 132.50
Check Before You Invest
Quality
Very GoodValuation
Somewhat UndervaluedCheck Valuation charts
Price Trend
Semi Strong
Is Anuh Pharma Ltd a good quality company?
Anuh Pharma Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Anuh Pharma Ltd performance compare with that of its Peers?
Revenue growth of Anuh Pharma Ltd vs industry peers?
Anuh Pharma Ltd revenue CAGR is 12.30%, compared to the industry median CAGR of 5.34%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Anuh Pharma Ltd?
Promoters hold 71.80% of the Anuh Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Anuh Pharma Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 4.5% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Anuh Pharma Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 21.6% | 16.3% | 20.6% | 10.9% | 19.8% | 19.3% | 21.1% | 29.7% | 19.8% | 16% | - |
| Value Creation Index ⓘ | 0.5 | 0.2 | 0.5 | -0.2 | 0.4 | 0.4 | 0.5 | 1.1 | 0.4 | 0.1 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 206 | 238 | 321 | 307 | 432 | 487 | 527 | 647 | 662 | 772 | 772 |
| Sales YoY Gr. | - | 15.5% | 34.7% | -4.3% | 40.7% | 12.7% | 8.4% | 22.7% | 2.2% | 16.7% | - |
| Adj EPS ⓘ | 1.9 | 1.5 | 2.5 | 1.8 | 2.3 | 3.1 | 3.7 | 5.8 | 4.7 | 4.3 | 4.1 |
| YoY Gr. | - | -20.6% | 63.6% | -27% | 26.6% | 31.8% | 19.9% | 57.3% | -18.5% | -9.5% | - |
| BVPS (₹) ⓘ | 14 | 14.9 | 16.4 | 16.2 | 19 | 21.3 | 24.1 | 29.1 | 32.5 | 35.1 | 35.1 |
| Adj Net Profit ⓘ | 19.4 | 15.4 | 25.3 | 18.5 | 23.4 | 30.7 | 36.9 | 58 | 47.3 | 42.8 | 41 |
| Cash Flow from Ops. ⓘ | 26.1 | 1.8 | 7.1 | 48.9 | -18.7 | 28.9 | 53.9 | 12.9 | 37.1 | -3 | - |
| Debt/CF from Ops. ⓘ | 0 | 1.3 | 0.6 | 0.9 | -0.7 | 0.1 | 0 | 0.2 | 0.3 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 15.8% | 12.3% | 13.5% | 16.7% | ||||
| Adj EPS ⓘ | 9.2% | 12.9% | 5.1% | -9.5% | ||||
| BVPSⓘ | 10.8% | 13.1% | 13.4% | 8% | ||||
| Share Price | 4.6% | 2.5% | 11.6% | -19.7% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 14.9 | 10.6 | 16.1 | 11.3 | 13.3 | 15.2 | 16.2 | 21.8 | 15.3 | 12.6 | 11.7 |
| Op. Profit Mgn % ⓘ | 11 | 8.6 | 10.8 | 10 | 10.5 | 10.1 | 10.2 | 11.8 | 9.7 | 8.9 | 7.6 |
| Net Profit Mgn % ⓘ | 9.4 | 6.5 | 7.9 | 6 | 5.4 | 6.3 | 7 | 9 | 7.1 | 5.5 | 5.3 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0.3 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 176 | 153 | 139 | 169 | 153 | 162 | 166 | 153 | 167 | 170 | 96 |
| Cash Conv. Cycle ⓘ | 58 | 62 | 54 | 47 | 32 | 50 | 48 | 50 | 62 | 68 | 52 |
Profit And Loss
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 206 | 238 | 321 | 307 | 432 | 487 | 527 | 647 | 662 | 772 |
| Operating Expenses ⓘ + | 183 | 220 | 291 | 284 | 387 | 439 | 476 | 571 | 600 | 714 |
| Operating Profit ⓘ | 23 | 18 | 30 | 23 | 45 | 47 | 52 | 76 | 62 | 57 |
| Operating Profit Margin (%) | 11.0% | 7.7% | 9.3% | 7.6% | 10.4% | 9.8% | 9.8% | 11.7% | 9.3% | 7.4% |
| Other Income ⓘ + | 8 | 7 | 5 | 4 | 11 | 5 | 6 | 12 | 9 | 9 |
| Interest ⓘ | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 |
| Depreciation ⓘ | 2 | 2 | 2 | 7 | 15 | 12 | 10 | 9 | 9 | 11 |
| Profit Before Tax ⓘ | 28 | 23 | 32 | 19 | 39 | 39 | 47 | 78 | 61 | 54 |
| Tax ⓘ | 8 | 7 | 9 | 5 | 10 | 9 | 11 | 18 | 14 | 13 |
| Profit After Tax | 20 | 17 | 23 | 14 | 28 | 31 | 36 | 60 | 47 | 41 |
| PAT Margin (%) | 9.7% | 6.9% | 7.3% | 4.7% | 6.6% | 6.3% | 6.9% | 9.3% | 7.2% | 5.3% |
| Adjusted EPS (₹) | 2.0 | 1.7 | 2.3 | 1.4 | 2.8 | 3.1 | 3.6 | 6.0 | 4.7 | 4.1 |
| Dividend Payout Ratio (%) | 31.20% | 41.70% | 29.50% | 48.20% | 26.40% | 28.70% | 27.70% | 20.90% | 15.90% | 36.60% |
Valuation of Anuh Pharma - Standalone
Analyst's Notes
No data found!
Balance Sheet
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 141 | 150 | 165 | 162 | 191 | 214 | 241 | 291 | 326 | 352 | |
| Debt + | 0 | 2 | 4 | 45 | 14 | 3 | 0 | 2 | 10 | 0 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 42 | 52 | 59 | 105 | 120 | 122 | 153 | 141 | 157 | 188 | |
| Others Liabilities ⓘ | 5 | 4 | 11 | 15 | 8 | 9 | 10 | 12 | 11 | 14 | |
| Total Liabilities ⓘ | 187 | 208 | 239 | 326 | 333 | 347 | 404 | 445 | 505 | 554 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 17 | 17 | 21 | 84 | 71 | 61 | 53 | 49 | 58 | 57 | |
| CWIP ⓘ | 0 | 6 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Investments ⓘ | 70 | 66 | 39 | 80 | 31 | 43 | 91 | 97 | 106 | 84 | |
| Inventories | 30 | 32 | 43 | 61 | 81 | 80 | 73 | 75 | 74 | 148 | |
| Trade Receivables | 57 | 71 | 75 | 81 | 107 | 136 | 171 | 190 | 216 | 239 | |
| Cash Equivalents | 6 | 8 | 11 | 3 | 20 | 16 | 7 | 8 | 20 | 8 | |
| Others Assets ⓘ | 7 | 8 | 17 | 18 | 21 | 11 | 10 | 25 | 30 | 18 | |
| Total Assets ⓘ | 187 | 208 | 239 | 326 | 333 | 347 | 404 | 445 | 505 | 554 | |
Cash Flow
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 26 | 2 | 7 | 49 | -19 | 29 | 54 | 13 | 37 | -3 |
| Cash Flow From Investing Activity ⓘ + | -20 | 2 | 3 | -77 | 52 | -8 | -43 | 1 | -20 | 18 |
| Cash Flow From Financing Activity ⓘ + | -4 | -5 | -7 | 22 | -33 | -19 | -12 | -9 | -5 | -26 |
| Net Cash Flow ⓘ | 2 | -1 | 3 | -5 | 0 | 2 | -2 | 5 | 12 | -11 |
Financial Ratio
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 15.43 | 11.38 | 14.87 | 8.75 | 16.12 | 15.11 | 15.9 | 22.56 | 15.34 | 12.1 |
| ROCE (%) | 21.61 | 16.31 | 20.56 | 10.87 | 19.75 | 19.33 | 21.05 | 29.66 | 19.77 | 16.02 |
| Asset Turnover Ratio | 1.15 | 1.23 | 1.44 | 1.12 | 1.34 | 1.44 | 1.41 | 1.53 | 1.4 | 1.47 |
| PAT to CFO Conversion(x) | 1.3 | 0.12 | 0.3 | 3.5 | -0.68 | 0.94 | 1.5 | 0.22 | 0.79 | -0.07 |
| Working Capital Days | ||||||||||
| Receivable Days | 110.50 | 95.70 | 82.40 | 89.30 | 77.90 | 90.20 | 105.70 | 101.40 | 111.10 | 106.50 |
| Inventory Days | 45 | 46.30 | 42.30 | 59.90 | 59.20 | 60 | 52.50 | 41.60 | 41 | 52.10 |
| Payable Days | 115.40 | 95.70 | 83.80 | 130.60 | 125.20 | 117.40 | 125.50 | 110.70 | 109.40 | 105.50 |
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Anuh Pharma Ltd FAQs
The current trading price of Anuh Pharma on 27-Jul-2026 10:19 is ₹79.57.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 26-Jul-2026 the market cap of Anuh Pharma stood at ₹793.1 Cr
The latest P/E ratio of Anuh Pharma as of 26-Jul-2026 is 19.32.
The latest P/B ratio of Anuh Pharma as of 26-Jul-2026 is 2.25.
The 52-week high of Anuh Pharma is ₹103.8 and the 52-week low is ₹66.72.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Anuh Pharma is ₹772 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Anuh Pharma Ltd is a good quality company.
The key valuation ratios of Anuh Pharma Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Anuh Pharma Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Anuh Pharma Ltd
Anuh Pharma incorporated in 1960, is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs). The company is part of the SK Group, which has evolved as a leading importer, exporter, distributor and manufacturer of bulk drugs, chemicals and pharmaceutical formulations.
The company has grown several immensely and earned recognition, besides gaining the trust of a strong customer base. Today, it is one of the largest producers of macrolides in the country.
Anuh Pharma has a product presence in Africa, Asia, Europe, Central/South America and the Middle East. The company's registered office is at E-17/3 and 17/4 MIDC, Tarapur, Boisar, Thane District 401506
Products
- Macrolides
- Higher Macrolides
- Quinolones
- Chloramphenicol
- Anti TB Drug
- Corticosteroids
Recognitions/Certifications
- Anuh Pharma has received ‘Star Export House’ certification from the Ministry of Commerce and Industry.
- The company received WHO-GMP certificate for carrying good manufacturing practices.
- Anuh Pharma has received ISO 9001:2000 certification
You have 3 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
